Synthesis and evaluation of radioiodinated cyclooxygenase-2 inhibitors as potential SPECT tracers for cyclooxygenase-2 expression

被引:35
|
作者
Kuge, Y [1 ]
Katada, Y
Shimonaka, S
Temma, T
Kimura, H
Kiyono, Y
Yokota, C
Minematsu, K
Seki, K
Tamaki, N
Ohkura, K
Saji, H
机构
[1] Kyoto Univ, Grad Sch Pharmceut Sci, Dept Pathofunct Bioanal, Kyoto, Japan
[2] Kyoto Univ Hosp, Fac Med, Radioisotopes Res Lab, Kyoto 6068507, Japan
[3] Natl Cardiovasc Ctr, Res Inst, Cerebrovasc Lab, Osaka 5658565, Japan
[4] Natl Cardiovasc Ctr, Res Inst, Cerebrovasc Lab, Osaka 5658565, Japan
[5] Hokkaido Univ, Cent Inst Isotope Sci, Sapporo, Hokkaido 0608638, Japan
[6] Hokkaido Univ, Cent Inst Isotope Sci, Sapporo, Hokkaido 0608638, Japan
[7] Hokkaido Univ, Grad Sch Med, Dept Nucl Med, Sapporo, Hokkaido 0608638, Japan
[8] Hokkaido Univ, Fac Pharmaceut Sci Hlth Sci, Dept Radiopharmaceut Chem, Sapporo, Hokkaido 0610293, Japan
关键词
cyclooxygenase-2 (COX-2); inhibitor; radioiodination; SPECT; radiopharmaceutical;
D O I
10.1016/j.nucmedbio.2005.10.004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Although several COX-2 inhibitors have recently been radiolabeled, their potential for imaging COX-2 expression remains unclear. In particular, the sulfonamide moiety of COX-2 inhibitors may cause slow blood clearance of the radiotracer, due to its affinity for carbonic anhydrase (CA) in erythrocytes. Thus, we designed a methyl sulfone-type analogue, 5-(4-iodophenyl)-1-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl-1H-pyrazole (IMTP). In this study, the potential of radioiodinated IMTP was assessed in comparison with a I-125-labeled celecoxib analogue with a sulfonamide moiety (I-125-IATP). Methods: The COX inhibitory potency was assessed by measuring COX-catalyzed oxidation by hydrogen peroxide. The biodistribution of I-125-IMTP and I-125-IATP was determined by the ex vivo tissue counting method in rats. Distribution of the labeled compounds to rat blood cells was measured. Results: The COX-2 inhibitory potency of IMTP (IC50=5.16 mu M) and IATP (IC50=8.20 mu M) was higher than that of meloxicam (IC50-29.0 mu M) and comparable to that of SC-58125 (IC50=1.36 mu M). The IC50 ratios (COX-1/COX-2) indicated the high isoform selectivity of IMTP and IATP for COX-2. Significant levels of I-125-IMTP and 125 MATP were observed in the kidneys and the brain (organs known to express COX-2). The blood clearance of I-125-IMTP was much faster than that of I-125-IATP. Distribution of (125) I-IATP to blood cells (88.0%) was markedly higher than that of I-125-IMTP (18.1%), which was decreased by CA inhibitors. Conclusions: Our results showed a high inhibitory potency and selectivity of IMTP for COX-2. The substitution of a sulfonamide moiety to a methyl sulfone moiety effectively improved the blood clearance of the compound, indicating the loss of the cross reactivity with CA in I-125-IMTP. I-123-IMTP may be a potential SPECT radiopharmaceutical for COX-2 expression. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:21 / 27
页数:7
相关论文
共 50 条
  • [41] Clinical experience with cyclooxygenase-2 inhibitors
    van Ryn, J
    Pairet, M
    INFLAMMATION RESEARCH, 1999, 48 (05) : 247 - 254
  • [42] Cyclooxygenase-2 specific inhibitors: a revolution?
    Berenbaum, F
    PRESSE MEDICALE, 1999, 28 (22): : 1182 - 1187
  • [44] Clinical experience with cyclooxygenase-2 inhibitors
    J. van Ryn
    M. Pairet
    Inflammation Research, 1999, 48 : 247 - 254
  • [45] Cyclooxygenase-2 inhibitors and the ethics of research
    Gherardi, CR
    Tealdi, JC
    Abud, A
    Gienini, O
    Genoud, G
    Kurlat, I
    MEDICINA-BUENOS AIRES, 2005, 65 (03) : 281 - 282
  • [46] Cardiovascular effects of cyclooxygenase-2 inhibitors
    Brophy, James M.
    CURRENT OPINION IN GASTROENTEROLOGY, 2007, 23 (06) : 617 - 624
  • [47] [123I]-Celecoxib Analogues as SPECT Tracers of Cyclooxygenase-2 in Inflammation
    Uddin, Md. Jashim
    Crews, Brenda C.
    Ghebreselasie, Kebreab
    Tantawy, Mohammed N.
    Marnett, Lawrence J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (02): : 160 - 164
  • [48] Enantiospecific, selective cyclooxygenase-2 inhibitors
    Kozak, KR
    Prusakiewicz, JJ
    Rowlinson, SW
    Marnett, LJ
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (09) : 1315 - 1318
  • [49] Cyclooxygenase-2 inhibitors in radiation therapy
    Deutsch, E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 10 - 10
  • [50] Cyclooxygenase-2 inhibitors and cardiovascular risk
    Solomon, Scott D.
    CURRENT OPINION IN CARDIOLOGY, 2006, 21 (06) : 613 - 617